Gemcitabine/nab-paclitaxel in first line treatment of advanced pancreatic cancer - head-to-head comparison with the mFOLFIRINOX regimen
{{output}}
Metastatic pancreatic ductal carcinoma (mPDAC) is one of the most lethal malignancies. The European Society for Medical Oncology (ESMO) guidelines recommend a gemcitabine doublet + nab-paclitaxel (Gem/Nab-P) or a modified FOLFIRINOX regimen (mFOLFIRINOX) as op... ...
